| Symbol | AVBP |
|---|---|
| Name | ARRIVENT BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 18 CAMPUS BLVD,SUITE 100, NEWTOWN SQUARE, Pennsylvania, 19073-3269, United States |
| Telephone | 240-780-6356 |
| Fax | — |
| — | |
| Website | https://www.arrivent.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001868279 |
| Description | ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. Additional info from NASDAQ: |
Director Parsey Merdad 🟢 acquired 13.6K shares (1 derivative) of ArriVent BioPharma, Inc. (AVBP) at $31.74 Transaction Date: Jun 18, 2026 | Filing ID: 076570
Read moreDirector Peterson Kristine 🟢 acquired 13.6K shares (1 derivative) of ArriVent BioPharma, Inc. (AVBP) at $31.74 Transaction Date: Jun 18, 2026 | Filing ID: 076569
Read moreDirector Hohneker John 🟢 acquired 13.6K shares (1 derivative) of ArriVent BioPharma, Inc. (AVBP) at $31.74 Transaction Date: Jun 18, 2026 | Filing ID: 076567
Read moreDirector Nolet Chris 🟢 acquired 13.6K shares (1 derivative) of ArriVent BioPharma, Inc. (AVBP) at $31.74 Transaction Date: Jun 18, 2026 | Filing ID: 076566
Read more(90% Positive) ARRIVENT BIOPHARMA, INC. (AVBP) Reports Q2 2026 Financial Results
Read moreNew Form 424B5 - ArriVent BioPharma, Inc. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001104659-26-058700 <b>Size:</b> 652 KB
Read moreArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
Read moreNew Form ARS - ArriVent BioPharma, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050350 <b>Size:</b> 4 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07185997 | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigat… | Phase3 | Non-Small-Cell Lung Cancer | Recruiting | 2025-12-17 | 2030-12-01 | ClinicalTrials.gov |
| NCT07066657 | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Phase1 | Locally Advanced or Metastatic Solid Tumors | Recruiting | 2025-07-25 | 2030-12-01 | ClinicalTrials.gov |
| NCT07010419 | A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for A… | Phase3 | NSCLC | Recruiting | 2025-05-28 | 2032-04-30 | ClinicalTrials.gov |
| NCT05607550 | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With… | Phase3 | Metastatic Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2023-06-01 | 2028-02-15 | ClinicalTrials.gov |
| NCT05364073 | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell L… | Phase1 | Non-Small Cell Lung Cancer (NSCLC) | Active_Not_Recruiting | 2022-06-30 | 2026-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| MRG007 | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT07066657 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| MRG007 | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT07066657 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Placebo | Other | Phase PHASE3 | NSCLC | RECRUITING | NCT07010419 |
| Firmonertinib | Other | Phase PHASE3 | NSCLC | RECRUITING | NCT07010419 |
| platinum-based chemotherapy | Drug | Phase PHASE3 | Metastatic Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05607550 |
| furmonertinib 160 mg oral, daily | Other | Phase PHASE3 | Metastatic Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05607550 |
| furmonertinib 240 mg oral, daily | Other | Phase PHASE3 | Metastatic Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05607550 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| MRG007 | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT07066657 |
| Furmonertinib | Other | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05364073 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| Firmonertinib | Other | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| EGFR-TKI inhibitor based on investigator's choice | DRUG | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| MRG007 | DRUG | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT07066657 |
| Placebo | DRUG | Phase PHASE3 | NSCLC | RECRUITING | NCT07010419 |
| Firmonertinib | DRUG | Phase PHASE3 | Non-Small-Cell Lung Cancer | RECRUITING | NCT07185997 |
| platinum-based chemotherapy | DRUG | Phase PHASE3 | Metastatic Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05607550 |
| furmonertinib 160 mg oral, daily | DRUG | Phase PHASE3 | Metastatic Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05607550 |
| furmonertinib 240 mg oral, daily | DRUG | Phase PHASE3 | Metastatic Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05607550 |
| Furmonertinib | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer (NSCLC) | ACTIVE_NOT_RECRUITING | NCT05364073 |